Clinical Trial Update: Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment [Phase 1]

View source ↗

Summary

Phase 1 repeated-dosing study in chronic kidney disease stage 3 patients on stable ACE inhibitors to assess safety and tolerability has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Snippet

Sponsor: Sanofi | Conditions: Chronic Kidney Disease | Phase 1 | Status: COMPLETED